| __timestamp | Amphastar Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 5758000 |
| Thursday, January 1, 2015 | 174172000 | 8423000 |
| Friday, January 1, 2016 | 150976000 | 11986000 |
| Sunday, January 1, 2017 | 149380000 | 15215000 |
| Monday, January 1, 2018 | 187681000 | 15356000 |
| Tuesday, January 1, 2019 | 190434000 | 16660000 |
| Wednesday, January 1, 2020 | 206506000 | 52459000 |
| Friday, January 1, 2021 | 238029000 | 75061000 |
| Saturday, January 1, 2022 | 250127000 | 87221000 |
| Sunday, January 1, 2023 | 293274000 | 83779000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. This analysis delves into the cost of revenue trends for Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Amphastar Pharmaceuticals has consistently shown a robust growth trajectory, with its cost of revenue increasing by approximately 84% over the decade, peaking in 2023. In contrast, Supernus Pharmaceuticals, while starting with a significantly lower cost base, has seen a remarkable increase of over 1,350% during the same period. This stark contrast highlights the differing operational scales and strategic focuses of these companies. Amphastar's steady growth reflects its expansive market reach, while Supernus's sharp rise suggests aggressive scaling and investment in new ventures. These insights provide a window into the financial strategies shaping the future of these pharmaceutical leaders.
Analyzing Cost of Revenue: Johnson & Johnson and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and Xencor, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Evotec SE